Objective
SELECT-IT aims to develop small molecules that specifically target bacterial intramolecular trans(IT)-sialidases. IT-sialidases from Ruminococcus species have been related to progression of inflammatory bowel diseases (IBD) and colorectal cancer (CRC). Following elucidation of the yet unknown mechanisms of action of IT-sialidases, I will rationally design candidate inhibitors, synthesise and characterise them, and assess their binding modes, inhibition efficacy and target selectivity. Inspired by strategies previously successful for antiviral drugs like Tamiflu, SELECT-IT will modify existing molecules such as Siastatin B, DANA, and 2,7-anhydro-Neu5Ac, as starting points to develop candidates that selectively inhibits bacterial sialidases while sparing human ones. The inhibitors will undergo systematic refinement through computer simulation (molecular dynamics, QM/MM and metadynamics) and experimental techniques (biochemical assays and NMR spectroscopy) to ensure high specificity. SELECT-IT aims to develop targeted inhibitors for managing bacterial infections linked to IBD and CRC, contributing directly to the creation of new therapeutic options.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicineoncology
- natural sciencesphysical sciencesopticsspectroscopy
You need to log in or register to use this function
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European FellowshipsCoordinator
08007 Barcelona
Spain